Generic Is good.(LETTERS)
Byline: THE WASHINGTON TIMES
Peter Ferrara's Aug. 29 Commentary column, "Poor prescriptions for health prospects," has done American consumers a great disservice. He erroneously suggested that generic drugs place consumers at risk and that the Greater Access to Affordable Pharmaceuticals Act (GAAP) alters intellectual property rights and federal approval requirements for generics. The facts prove Mr. Ferrara wrong on both counts.
GAAP, a modest piece of compromise legislation, levels the playing field between powerful brand companies and pro-consumer generic companies by closing the loopholes that some pharmaceutical companies have exploited to prevent consumers from having timely access to more affordable generics. GAAP will save consumers, employers, taxpayers and federal and state government programs as much as $60 billion in unnecessary health care costs over the next decade. It creates these savings without threatening pharmaceutical innovation or altering patent or intellectual property rights.
For nearly two decades, FDA-approved generic drugs have been saving consumers billions of dollars each year without compromising patient safety. …